MedTrace Logo

A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects

NCT02859259 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2017-05-15

No results posted yet for this study

Summary

An oral dose in healthy subjects to determine the relative bioavailabilty of BMS-626529 administered as BMS-663068

Conditions

  • Infection, Human Immunodeficiency Virus

Interventions

DRUG

BMS-663068 (1 tablet at 600 mg)

BMS-663068 (1 tablet at 600 mg). A single dose of BMS-663068 administered orally as specified.

DRUG

BMS-663068 (4 tablets at 150 mg each tablet)

BMS-663068 (4 tablets at 150 mg each tablet). A single dose (4 tablets) of BMS-663068 administered orally as specified.

Sponsors & Collaborators

  • ViiV Healthcare

    lead INDUSTRY

Principal Investigators

  • GSK Clinical Trials · ViiV Healthcare

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-12
Primary Completion
2016-08-12
Completion
2016-08-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02859259 on ClinicalTrials.gov